Certainly don't know if it will get approved. Many dubious elements in the P3 trial and look how long MHRA is taking for the review. There have likely been one or more RFIs requiring NWBO to respond to MHRA questions. Never a good sign. But even if it gets approved, UK is a disaster market for personalized oncology therapies. None of them have gotten NICE coverage other than the limited coverage from the NICE charity (Gilead gets 100 treatments a year). NWBO certainly doesn't have the cash to survive if the rationed charity coverage and get the normal low NICE reimbursement for a very expensive treatment.
Market Data 
Markets 
AI
